|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Borley J, Wilhelm-Benartzi C, Brown R and
Ghaem-Maghami S: Does tumour biology determine surgical success in
the treatment of epithelial ovarian cancer? A systematic literature
review. Br J Cancer. 107:1069–1074. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
du Bois A, Quinn M, Thigpen T, Vermorken
J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A,
Cervantes A, et al Gynecologic Cancer Intergroup, AGO-OVAR, ANZGOG,
EORTC, GEICO, GINECO, GOG, JGOG, MRC/NCRI, NCIC-CTG, NCI-US, NSGO,
RTOG, SGCTG, IGCS, Organizational team of the two prior
International OCCC, : 2004 consensus statements on the management
of ovarian cancer: Final document of the 3rd International
Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference
(GCIG OCCC 2004). Ann Oncol. 16 (Suppl 8):viii7–viii12. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Japan Society of Gynecologic Oncology, .
Formulation committee of the treatment guidelines for ovarian.
simplehttps://jsgo.or.jp/guideline/ransou2015.htmlSeptember
1–2017
|
|
5
|
Ozols RF, Bundy BN, Greer BE, Fowler JM,
Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM
and Baergen R; Gynecologic Oncology Group, : Phase III trial of
carboplatin and paclitaxel compared with cisplatin and paclitaxel
in patients with optimally resected stage III ovarian cancer: A
Gynecologic Oncology Group study. J Clin Oncol. 21:3194–3200. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Friedlander M, Trimble E, Tinker A,
Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S,
Pujade-Lauraine E, Sehouli J, et al Gynecologic Cancer InterGroup,
: Clinical trials in recurrent ovarian cancer. Int J Gynecol
Cancer. 21:771–775. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Markman M, Rothman R, Hakes T, Reichman B,
Hoskins W, Rubin S, Jones W, Almadrones L and Lewis JL Jr:
Second-line platinum therapy in patients with ovarian cancer
previously treated with cisplatin. J Clin Oncol. 9:389–393. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kyrgiou M, Salanti G, Pavlidis N,
Paraskevaidis E and Ioannidis JP: Survival benefits with diverse
chemotherapy regimens for ovarian cancer: Meta-analysis of multiple
treatments. J Natl Cancer Inst. 98:1655–1663. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Spriggs KA, Bushell M and Willis AE:
Translational regulation of gene expression during conditions of
cell stress. Mol Cell. 40:228–237. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Truitt ML and Ruggero D: New frontiers in
translational control of the cancer genome. Nat Rev Cancer.
16:288–304. 2016.Erratum in: Nat Rev Cancer 17: 332, 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Marcel V, Catez F and Diaz JJ: p53, a
translational regulator: Contribution to its tumour-suppressor
activity. Oncogene. 34:5513–5523. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wooderchak WL, Zang T, Zhou ZS, Acuña M,
Tahara SM and Hevel JM: Substrate profiling of PRMT1 reveals amino
acid sequences that extend beyond the ‘RGG’ paradigm. Biochemistry.
47:9456–9466. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yoshimatsu M, Toyokawa G, Hayami S, Unoki
M, Tsunoda T, Field HI, Kelly JD, Neal DE, Maehara Y, Ponder BA, et
al: Dysregulation of PRMT1 and PRMT6, type I arginine
methyltransferases, is involved in various types of human cancers.
Int J Cancer. 128:562–573. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hirata Y, Katagiri K, Nagaoka K, Morishita
T, Kudoh Y, Hatta T, Naguro I, Kano K, Udagawa T, Natsume T, et al:
TRIM48 promotes ASK1 activation and cell death through
ubiquitination-dependent degradation of the ASK1-negative regulator
PRMT1. Cell Rep. 21:2447–2457. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sinicrope FA, Ruan SB, Cleary KR, Stephens
LC, Lee JJ and Levin B: bcl-2 and p53 oncoprotein expression during
colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ghosh Cisplatin S.: The first metal based
anticancer drug. Bioorg Chem. 88:1029252019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Amable L: Cisplatin resistance and
opportunities for precision medicine. Pharmacol Res. 106:27–36.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Infantino S, Benz B, Waldmann T, Jung M,
Schneider R and Reth M: Arginine methylation of the B cell antigen
receptor promotes differentiation. J Exp Med. 207:711–719. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sakamaki J, Daitoku H, Ueno K, Hagiwara A,
Yamagata K and Fukamizu A: Arginine methylation of BCL-2 antagonist
of cell death (BAD) counteracts its phosphorylation and
inactivation by Akt. Proc Natl Acad Sci USA. 108:6085–6090. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu Z, Chen T, Hébert J, Li E and Richard
S: A mouse PRMT1 null allele defines an essential role for arginine
methylation in genome maintenance and cell proliferation. Mol Cell
Biol. 29:2982–2996. 2009.Erratum in: Mol Cell Biol 37: e00298-17,
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dominguez-Sola D, Kung J, Holmes AB, Wells
VA, Mo T, Basso K and Dalla-Favera R: The FOXO1 transcription
factor instructs the germinal center dark zone program. Immunity.
43:1064–1074. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kuhn P, Chumanov R, Wang Y, Ge Y, Burgess
RR and Xu W: Automethylation of CARM1 allows coupling of
transcription and mRNA splicing. Nucleic Acids Res. 39:2717–2726.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim DI, Park MJ, Choi JH, Kim IS, Han HJ,
Yoon KC, Park SW, Lee MY, Oh KS and Park SH: PRMT1 and PRMT4
regulate oxidative stress-induced retinal pigment epithelial cell
damage in SIRT1-dependent and SIRT1-independent manners. Oxid Med
Cell Longev. 2015:6179192015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mathioudaki K, Papadokostopoulou A,
Scorilas A, Xynopoulos D, Agnanti N and Talieri M: The PRMT1 gene
expression pattern in colon cancer. Br J Cancer. 99:2094–2099.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Park MJ, Kim DI, Lim SK, Choi JH, Kim JC,
Yoon KC, Lee JB, Lee JH, Han HJ, Choi IP, et al:
Thioredoxin-interacting protein mediates hepatic lipogenesis and
inflammation via PRMT1 and PGC-1α regulation in vitro and in vivo.
J Hepatol. 61:1151–1157. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Siroen MP, Teerlink T, Nijveldt RJ, Prins
HA, Richir MC and van Leeuwen PA: The clinical significance of
asymmetric dimethylarginine. Annu Rev Nutr. 26:203–228. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sydow K, Mondon CE and Cooke JP: Insulin
resistance: Potential role of the endogenous nitric oxide synthase
inhibitor ADMA. Vasc Med. 10 (Suppl 1):S35–S43. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li B, Liu L, Li X and Wu L: miR-503
suppresses metastasis of hepatocellular carcinoma cell by targeting
PRMT1. Biochem Biophys Res Commun. 464:982–987. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhou W, Yue H, Li C, Chen H and Yuan Y:
Protein arginine methyltransferase 1 promoted the growth and
migration of cancer cells in esophageal squamous cell carcinoma.
Tumour Biol. 37:2613–2619. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chuang CY, Chang CP, Lee YJ, Lin WL, Chang
WW, Wu JS, Cheng YW, Lee H and Li C: PRMT1 expression is elevated
in head and neck cancer and inhibition of protein arginine
methylation by adenosine dialdehyde or PRMT1 knockdown
downregulates proliferation and migration of oral cancer cells.
Oncol Rep. 38:1115–1123. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Avasarala S, Van Scoyk M, Karuppusamy
Rathinam MK, Zerayesus S, Zhao X, Zhang W, Pergande MR, Borgia JA,
DeGregori J, Port JD, et al: PRMT1 is a novel regulator of
epithelial-mesenchymal-transition in non-small cell lung cancer. J
Biol Chem. 290:13479–13489. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Baldwin RM, Bejide M, Trinkle-Mulcahy L
and Côté J: Identification of the PRMT1v1 and PRMT1v2 specific
interactomes by quantitative mass spectrometry in breast cancer
cells. Proteomics. 15:2187–2197. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Papadokostopoulou A, Mathioudaki K,
Scorilas A, Xynopoulos D, Ardavanis A, Kouroumalis E and Talieri M:
Colon cancer and protein arginine methyltransferase 1 gene
expression. Anticancer Res. 29:1361–1366. 2009.PubMed/NCBI
|
|
36
|
Cho JH, Lee MK, Yoon KW, Lee J, Cho SG and
Choi EJ: Arginine methylation-dependent regulation of ASK1
signaling by PRMT1. Cell Death Differ. 19:859–870. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Baldwin RM, Morettin A and Côté J: Role of
PRMTs in cancer: Could minor isoforms be leaving a mark? World J
Biol Chem. 5:115–129. 2014.PubMed/NCBI
|
|
38
|
Musiani D, Giambruno R, Massignani E,
Ippolito MR, Maniaci M, Jammula S, Manganaro D, Cuomo A, Nicosia L,
Pasini D and Bonaldi T: PRMT1 is recruited via DNA-PK to chromatin
where it sustains the senescence-associated secretory phenotype in
response to cisplatin. Cell Rep. 30:1208–1222.e9. 2020. View Article : Google Scholar : PubMed/NCBI
|
